Why
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Supporting you to treat a
range of fungal pathogens in your at-risk HIV patients4–7
Liposomal Amphotericin B was chosen to help
treat Mustafa's Cryptococcus neoformans infection
because it demonstrates:
Reduced nephrotoxicity vs. conventional
amphotericin B formulations1,8–15
The liposomal delivery system reduces off-target toxicity
by encapsulating amphotericin B until it reaches the fungal
cell wall.10,16 Close monitoring of electrolytes and renal
function during Liposomal Amphotericin B treatment is
important, especially at escalated doses.1,17 Renal
adversereactions may still occur.1
Improved tissue penetration vs.
conventional amphotericin B16
Liposomal Amphotericin B demonstrates improved
tissue penetration with sustained drug levels and activity
in key target tissues, including the brain, lungs, kidneys,
liver and spleen, vs. conventional amphotericin B.*16
A well-established tolerability and
safety profile**,1
Very common adverse events associated with
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.1
*The clinical relevance of these animal studies in humans is unknown.16
**Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 6
Liposomal Amphotericin B initiated
DAY 13
Resolution of symptoms
Why
Liposomal
Amphotericin
B
DAY 6
Liposomal Amphotericin B initiated
Liposomal Amphotericin B was chosen to help treat Mustafa's Cryptococcus neoformans infection because it demonstrates:
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Supporting you to treat a range of fungal pathogens
in your at-risk HIV patients4–7
The liposomal delivery system reduces off-target
toxicity by encapsulating amphotericin B until it
reaches the fungal cell wall.10,16 Close monitoring
of electrolytes and renal function during
Liposomal Amphotericin B treatment is important,
especially at escalated doses.1,17 Renal adverse
reactions may still occur.1
Very common adverse events associated
with Liposomal Amphotericin B treatment
include rigors, pyrexia, hypokalaemia,
nausea and vomiting.1
Liposomal Amphotericin B demonstrates improved
tissue penetration with sustained drug levels and
activity in key target tissues, including the brain,
lungs, kidneys, liver and spleen, vs. conventional
amphotericin B.*16
*The clinical relevance of these animal studies in humans is unknown.16
**Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 13
Resolution of symptoms
Reduced nephrotoxicity vs. conventional
amphotericin B formulations1,8–15
Improved tissue penetration vs.
conventional amphotericin B16
A well-established tolerability and
safety profile**,1